ARCHIVES

Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Deadline June 1 For New ACS Prevention Awards; Money Available To Fund Five More

April 11, 1980

ACCC Annual Meeting Jan. 27-29; Upton To speak

November 4, 1977

Roche Markets CMV Test in Europe

April 29, 2011

Chronobiology Review Still Delayed

May 5, 1989

Pryor Calls For Price Regulation Of Drugs In Health Reform

February 12, 1993

UT Health Science Center dedicates new Children’s Cancer Research Institute.

March 12, 2004